Uses
Monoclonal Anti-MYC-FITC , (C-terminal) antibody produced in mouse has been used in immunofluorescence and flow cytometry.
Uses
Use Anti-c-myc for the detection of native human c-myc protein and recombinant epitope-tagged proteins that contain the c-myc epitope using:
- Dot blots
- Immunocytochemistry
- Immunoprecipitation
- Western blots
- Immunohistochemistry.
General Description
The Anti-c-Myc peroxidase conjugate rabbit antibody reacts with c-Myc tagged fusion proteins. It recognizes the c-Myc tag sequence expressed at either the amino- or the carboxyl-terminus.
Biochem/physiol Actions
The cellular myelocytomatosis (c-myc) oncogene has a crucial role in cellular proliferation, differentiation, apoptosis and acts as transcriptional regulator of gene expression. c-myc expression is essential and sufficient to assist most of the cells to enter DNA synthetic (S) phase of the cell cycle. The encoded protein plays a crucial role in vasculogenesis and angiogenesis during cancer development and progression. c-myc interacts with its binding partner Max and activates the transcription of growth promoting genes such as cyclin D2 and ornithine decarboxylase. It also represses the transcription of multiple genes, especially p21 and p27, by binding to the transcription initiator element (Inr) in a complex with Max and either Sp1 (specificity protein 1) or Miz1 (Myc-interacting zinc finger protein 1). Overexpression of MYC in DLBCL (diffuse large B-cell lymphoma) results in poor outcome and invasive treatment when medicated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).
